Preparation and evaluation of olanzepine microsphere for treatment of depression and obessive compulsive disorder

The clinically important dopamine receptor employed in schizophrenia was proven to be the source of the second generation atypical antipsychotic medication that was licensed in UA in 1996. However, less than 60% of it is absorbed due to considerable first-pass metabolism. The goal of this research was to create a microsphere of Olanzapine in order to increase its bioavailability and prevent hepatic first pass metabolism. Different concentrations of sodium alginate and carbopol polymer were used in a factorial design. They were assessed test like Porsolt swim, tail suspension, elevated plus maze, and tail suspension test in animals (Wistar albino rats and mice) in order to assess the effectiveness of antidepressants. The result showed a considerable reduction in immobility duration when compared to group I (normal).An optimized batch study using wistar rats was conducted to assess the antidepressant impact of administering Olanzapine microsphere over A.P.I.